company background image
ABT logo

Abbott Laboratories NYSE:ABT Stock Report

Last Price

US$116.64

Market Cap

US$202.4b

7D

4.1%

1Y

13.6%

Updated

21 Feb, 2024

Data

Company Financials +

ABT Stock Overview

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

ABT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance2/6
Financial Health6/6
Dividends5/6

Rewards

Risk Analysis

No risks detected for ABT from our risk checks.

Abbott Laboratories Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abbott Laboratories
Historical stock prices
Current Share PriceUS$116.64
52 Week HighUS$117.19
52 Week LowUS$89.67
Beta0.75
1 Month Change2.15%
3 Month Change13.57%
1 Year Change13.58%
3 Year Change-4.69%
5 Year Change51.03%
Change since IPO31,750.49%

Recent News & Updates

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Feb 08
Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Recent updates

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Feb 08
Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

Jan 29

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26
The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Dec 28

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Dec 27
Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Dec 03

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Nov 29
Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market

Nov 26

Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?

Nov 01

Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up

Oct 24
Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up

Abbott: A Diversified Health Care Company With Strong Underlying Growth

Oct 20

Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience

Sep 29

Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price

Sep 26
Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price

Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income

Sep 17

We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt

Aug 13
We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt

Abbott: This Dividend King Is Ready For Takeoff

Jul 31

Abbott Laboratories Q2 2023 Earnings Preview: Expect Incremental Improvement

Jul 17

The Big Trends: New Frontiers in Healthcare

Jul 13
The Big Trends: New Frontiers in Healthcare

Abbott Laboratories (NYSE:ABT) Is Experiencing Growth In Returns On Capital

Jul 12
Abbott Laboratories (NYSE:ABT) Is Experiencing Growth In Returns On Capital

Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Jun 25
Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Offers Promising Buying Opportunity (Technical Analysis)

Jun 23

Abbott Laboratories: Organic Growth Will Carry It Through

May 25

We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt

May 10
We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt

There's Been No Shortage Of Growth Recently For Abbott Laboratories' (NYSE:ABT) Returns On Capital

Apr 10
There's Been No Shortage Of Growth Recently For Abbott Laboratories' (NYSE:ABT) Returns On Capital

An Intrinsic Calculation For Abbott Laboratories (NYSE:ABT) Suggests It's 32% Undervalued

Mar 14
An Intrinsic Calculation For Abbott Laboratories (NYSE:ABT) Suggests It's 32% Undervalued

Abbott Acquires Cardiovascular Systems: Key Takeaways For Investors

Feb 15

Abbott to acquire heart device maker Cardiovascular Systems for $20/share

Feb 09

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Feb 02
These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Abbott wins FDA approval of Proclaim XR for diabetic peripheral neuropathy

Jan 26

Abbott receives FDA approval for transcatheter aortic valve implantation system

Jan 17

Shareholder Returns

ABTUS Medical EquipmentUS Market
7D4.1%1.4%-0.5%
1Y13.6%11.3%22.3%

Return vs Industry: ABT exceeded the US Medical Equipment industry which returned 11.3% over the past year.

Return vs Market: ABT underperformed the US Market which returned 22.3% over the past year.

Price Volatility

Is ABT's price volatile compared to industry and market?
ABT volatility
ABT Average Weekly Movement2.1%
Medical Equipment Industry Average Movement8.1%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: ABT has not had significant price volatility in the past 3 months.

Volatility Over Time: ABT's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1888114,000Robert Fordhttps://www.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Abbott Laboratories Fundamentals Summary

How do Abbott Laboratories's earnings and revenue compare to its market cap?
ABT fundamental statistics
Market capUS$202.39b
Earnings (TTM)US$5.70b
Revenue (TTM)US$40.11b

35.5x

P/E Ratio

5.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABT income statement (TTM)
RevenueUS$40.11b
Cost of RevenueUS$17.92b
Gross ProfitUS$22.19b
Other ExpensesUS$16.49b
EarningsUS$5.70b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)3.29
Gross Margin55.32%
Net Profit Margin14.21%
Debt/Equity Ratio37.8%

How did ABT perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

63%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.